Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EVX-02 + nivolumab
- Development stage
- Discontinued
- Lead developer
- Evaxion
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular (EVX-02), Intravenous (nivolumab)
01
Overview
EVX-02 + nivolumab is a **combination therapy** of a personalized DNA-based neoantigen cancer vaccine (EVX-02) and a checkpoint inhibitor (nivolumab) for cancer immunotherapy, specifically being investigated in resected malignant melanoma. EVX-02 is developed for each patient individually using Evaxion's AI platform (PIONEER) to identify relevant neoantigens from the patient’s tumor—these are encoded in a plasmid administered as the vaccine. Nivolumab, a monoclonal antibody against PD-1, is used to block immune checkpoint pathways and enhance T-cell–mediated antitumor responses. The combination induces robust, specific CD4+ and CD8+ T-cell activation against tumor neoantigens. Both components are aimed at improving immune recognition and killing of cancer cells. Clinical data from a Phase I/IIa trial indicated promising safety, tolerability, and immunogenicity, with all treated patients relapse-free within the study period[1][2][3][4].
- Brand names
- nivolumab (Opdivo)
- Other names
- EVX-02 + nivolumabEVX-02 and nivolumabEVX02 and nivolumabEVX 02 and nivolumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)Neoantigen (Patient-specific neoantigen epitope)pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on EVX-02 + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EVX-02 + nivolumab.